[Form 4] Transcat Inc Insider Trading Activity
Lee D. Rudow, President, CEO and Director of Transcat, Inc. (TRNS), reported multiple equity transactions dated 08/21/2025. The filing shows a disposition of 93,864 shares of Transcat common stock and the grant of several restricted stock unit (RSU) awards that convert one-for-one into common shares: 14,782, 12,500, 3,925, and 8,785 RSUs. Specific vesting schedules are provided for each award, with portions vesting on March 28, 2026, March 27, 2027, and March 25, 2028 as noted.
In addition, a stock option covering 10,000 shares with an exercise price of $63.17 is reported as fully exercisable as of the report date. The report was signed by an attorney-in-fact on behalf of Mr. Rudow on 08/25/2025. The RSU grants are identified as issued under the Transcat, Inc. 2021 Stock Incentive Plan and are described as transactions exempt under Rule 16b-3.
- None.
- None.
Insights
TL;DR: CEO reported significant disposal of common stock and receipt of multiple time‑based RSU grants with staggered vesting.
The Form 4 documents a disposition of 93,864 common shares alongside grant of RSUs totaling 39, - see award lines (14,782; 12,500; 3,925; 8,785) that convert one-for-one to common stock and have defined vesting dates in 2026–2028. The awards are issued under the company’s 2021 Stock Incentive Plan and noted as exempt under Rule 16b-3, indicating standard insider compensation mechanics rather than a non‑routine transfer. The disclosure by the President & CEO meets Section 16 reporting requirements.
TL;DR: The package mixes immediate liquidity (share disposition) with long-term retention via RSUs and an exercisable option.
The report shows an immediate sale/transfer of 93,864 shares on 08/21/2025 while the officer retains or receives time‑vested incentives: RSUs with vesting in 2026–2028 and a fully exercisable 10,000‑share option at $63.17. This structure aligns with common executive compensation practices that balance near‑term monetization with multi‑year retention incentives. All grants are recorded as exempt under Rule 16b-3, signaling they follow typical company plan procedures.